Search results for "immunotherapy"

showing 10 items of 830 documents

Prevention of the post-chemotherapy relapse of tuberculous infection by combined immunotherapy

2008

Summary We report that a recently developed combined immunotherapy (CIT) has the capacity to prevent a spontaneous relapse of replicating Mycobacterium tuberculosis bacilli in the lungs of BALB/c, C57Bl/6 or C3H/HeJ strains of mice, following 4 weeks of non-sterilising treatment with isoniazid and rifampicin. The CIT regimen, represented by recombinant IFNγ, anti-α crystalline monoclonal IgA antibody and IL-4 neutralizing polyclonal antibody, reduced the 8-week relapse of viable bacterial counts in the lungs most significantly, when CIT was inoculated during the 5th week post infection, i.e. during the 3rd week of chemotherapy. Although CIT enhanced lung granuloma area, nitric oxide, cytoki…

MaleMicrobiology (medical)TuberculosisTuberculosiAntibodiemedicine.medical_treatmentImmunologyAntitubercular AgentsColony Count MicrobialMicrobiologyAntibodiesMycobacterium tuberculosisInterferon-gammaMiceAdjuvants ImmunologicRecurrencemedicineAnimalsalpha-CrystallinsRelapseTuberculosis PulmonaryCytokineMice Inbred BALB CMice Inbred C3HChemotherapyLungbiologybusiness.industryTuberculosis; Cytokines; Antibodies; Immunotherapy; RelapseIsoniazidMycobacterium tuberculosisImmunotherapybiology.organism_classificationmedicine.diseaseCombined Modality TherapyRecombinant ProteinsImmunoglobulin AMice Inbred C57BLRegimenInfectious Diseasesmedicine.anatomical_structureModels AnimalImmunologyInterleukin-4ImmunotherapybusinessRifampicinmedicine.drugTuberculosis
researchProduct

Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma.

2018

Mounting an effective immune response against cancer requires the activation of innate and adaptive immune cells. Metastatic melanoma is the most aggressive form of skin cancer. While immunotherapies have shown a remarkable success in melanoma treatment, patients develop resistance by mechanisms that include the establishment of an immune suppressive tumor microenvironment. Thus, understanding how metastatic melanoma cells suppress the immune system is vital to develop effective immunotherapies against this disease. In this study, we find that macrophages (MOs) and dendritic cells (DCs) are suppressed in metastatic melanoma and that the Ig-CDR-based peptide C36L1 is able to restore MOs and …

MaleModels MolecularImmunologyMelanoma Experimentalchemical and pharmacologic phenomenaModels Biologicalimmune responseMiceStructure-Activity RelationshipT-Lymphocyte SubsetsAnimalsdendritic cellsNeoplasm MetastasisReceptors ImmunologicMacrophage Migration-Inhibitory FactorsMelanomaOriginal ResearchMacrophagesHistocompatibility Antigens Class IIImmunitypeptide-based immunotherapyAntigens Differentiation B-LymphocyteCD74macrophage migration inhibitory factorPeptidesProtein BindingSignal Transductionmetastatic melanomaFrontiers in immunology
researchProduct

Leishmaniasis, autoimmune rheumatic disease, and anti–tumor necrosis factor therapy, Europe.

2009

We report 2 cases of leishmaniasis in patients with autoimmune rheumatic diseases in Greece. To assess trends in leishmaniasis reporting in this patient population, we searched the literature for similar reports from Europe. Reports increased during 2004–2008, especially for patients treated with anti–tumor necrosis factor agents.

MaleNecrosisgenetic structuresEpidemiologymedicine.medical_treatmentAnti-Inflammatory Agentslcsh:MedicineAnti-TNF0302 clinical medicineRisk FactorsMedicine030212 general & internal medicinerheumatic diseaseLeishmaniasisLeishmaniaimmunosuppressionbiologyDispatchAntibodies MonoclonalRheumatic diseaseImmunosuppressionMiddle Aged3. Good healthEuropeTreatment OutcomeInfectious DiseasesRheumatic feverFemaleTumor necrosis factor alphaImmunotherapymedicine.symptomMicrobiology (medical)medicine.medical_specialtytumor necrosis factor030231 tropical medicineletterparasiteslcsh:Infectious and parasitic diseases03 medical and health sciencesRheumatic DiseasesAnimalsHumansautoimmune diseaseslcsh:RC109-216Letters to the EditorAged030203 arthritis & rheumatologyTumor Necrosis Factor-alphabusiness.industryscreeninglcsh:RLeishmaniasisImmunotherapyLeishmaniabiology.organism_classificationmedicine.diseaseDermatologyInfliximabAnti-Tumor Necrosis Factor TherapyImmunologysense organsbusinessEmerging Infectious Diseases
researchProduct

Cetuximab in small bowel adenocarcinoma: a new friend?

2010

Sir, Small bowel adenocarcinoma (SBA) is a rare and aggressive tumour. SBA in the United States increased from 5.7 cases per million in 1973 to 7.3 cases per million in 2004 (Surveillance Epidemiology and End Results (SEER), 1973–2004 database; Jemal et al (2009). Surgery is the mainstay of treatment, even if chemotherapy in advanced disease has been associated with an increased survival. The most effective agents include 5-FU, irinotecan, platinum agents and gemcitabine (Fishman et al, 2006; Speranza et al, 2010). The molecular characterisation of this cancer could help to improve prognosis. Specifically, the frequency of KRAS gene mutations is similar than in colorectal cancer (Ari et al,…

MaleOncologyIntestinal NeoplasmCancer Researchmedicine.medical_specialtySurvivalSettore MED/06 - Oncologia MedicaColorectal cancerAdenocarcinoma; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Combined Modality Therapy; Female; Humans; Immunotherapy; Intestinal Neoplasms; Intestine Small; Male; Middle Aged; Survival; Oncology; Cancer ResearchCetuximabAdenocarcinomaGene mutationAntibodies Monoclonal Humanizedmedicine.disease_causeAntineoplastic AgentInternal medicineIntestine SmallmedicineAntineoplastic Combined Chemotherapy ProtocolCetuximabbusiness.industryAntibodies MonoclonalCancerMiddle Agedmedicine.diseaseCombined Modality TherapyGemcitabineSurgeryIrinotecanOncologyFOLFIRICamptothecinFemaleImmunotherapyKRASbusinessHumanmedicine.drug
researchProduct

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score.

2022

Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). However, biomarkers that predict treatment success and survival remain an unmet need.Patients with HCC put on PD-(L)1-based immunotherapy were included in a training set (n = 190; 6 European centers) and a validation set (n = 102; 8 European centers). We investigated the prognostic value of baseline variables on overall survival using a Cox model in the training set and developed the easily applicable CRAFITY (CRP and AFP in ImmunoTherapY) score. The score was validated in the independent, external cohort, and evaluated in a cohort of patie…

MaleOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularBevacizumabAntineoplastic Agents610 Medicine & healthAntibodies Monoclonal HumanizedAntineoplastic Agents ImmunologicalAtezolizumabGermanyInternal medicinemedicineHumans610 Medicine & healthAgedProportional Hazards ModelsRetrospective StudiesHepatologyProportional hazards modelbusiness.industryLiver NeoplasmsMiddle AgedSorafenibPrognosismedicine.diseaseBevacizumabRegimenTreatment OutcomeItalyHepatocellular carcinomaCohortFemaleImmunotherapyLiver cancerbusinessSwitzerlandmedicine.drug
researchProduct

Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone …

2003

Immunotherapy is a recognized treatment for allergic respiratory diseases.

MaleParietaria; Androstadienes; Skin; Double-Blind Method; Combined Modality Therapy; Humans; Asthma; Child; Desensitization Immunologic; Anti-Allergic Agents; Plant Proteins; Pollen; Rhinitis Allergic Seasonal; Allergens; Treatment Outcome; Administration Inhalation; Adolescent; Administration Sublingual; Male; FemaleParietaria pollenAdolescentAdministration Sublingualsublingual immunotherapylate skin responsechildrenDouble-Blind Methodchildren; early skin response; fluticasone; late skin response; Parietaria pollen; sublingual immunotherapy; visual analog scoreAdministration InhalationChildSkinAndrostadieneAllergenearly skin responsefluticasonePlant ProteinRhinitis Allergic SeasonalCombined Modality TherapyAsthmaAnti-Allergic Agentvisual analog scoreParietariaTreatment OutcomeDesensitization ImmunologicPollenFemaleHuman
researchProduct

The prognostic impact of blood group-related antigen Lewis Y and the ABH blood groups in resected non-small cell lung cancer.

2007

The blood group antigen Lewis Y is expressed on epithelial tumors of the respiratory, digestive and reproductive system. Despite being regarded as an attractive target for immunotherapy, its function is still not well defined and its prognostic value remains a subject of discussion. Eighty-three paraffin-embedded tissue sections of non-small cell lung cancer (NSCLC) patients in stage I-IIIa, who underwent surgical resection of the primary tumor (73% male; 43% adenocarcinoma), were stained with a new, highly specific monoclonal antibody against Lewis Y (clone A70-C/C8). A positive Lewis Y expression was observed in 51% of patients; adenocarcinomas were favorably stained (67%). Multivariate a…

MalePathologymedicine.medical_specialtyLung Neoplasmsmedicine.drug_classmedicine.medical_treatmentMonoclonal antibodyABO Blood-Group SystemImmunoenzyme TechniquesLewis Blood Group AntigensAntigenAntigens NeoplasmCarcinoma Non-Small-Cell LungmedicineCarcinomaBiomarkers TumorHumansReproductive systemRespiratory systemLung cancerSurvival rateNeoplasm Stagingbusiness.industryGeneral MedicineImmunotherapyMiddle Agedmedicine.diseasePrognosisSurvival RatebusinessFollow-Up StudiesTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
researchProduct

Therapy of Peritoneal Murine Cancer with Biological Response Modifiers

1985

We have used a murine renal adenocarcinoma of spontaneous origin (Renca) inplanted in the peritoneal cavity to study the therapeutic potential of biological response modifiers (BRMs) used alone or in conjunction with chemotherapy. This tumor model is therapeutically challenging since following intraperitoneal (i.p.) injection, the tumor grows progressively with hemorrhagic ascites, abdominal metastases to lymph nodes, liver, spleen, most serous membranes, and, in some animals, metastases to extra-abdominal sites (lungs). In the absence of therapy, death invariably occurs within 36 +/- 2 days. The tumor is efficiently lysed in 4 hours by peritoneal cells isolated from mice treated with BRMs.…

MalePathologymedicine.medical_specialtyPolymersPyran Copolymermedicine.medical_treatmentImmunologySpleenAdenocarcinomaToxicologyMicePeritoneal cavitymedicineAnimalsBiological response modifiersPeritoneal NeoplasmsPharmacologyMice Inbred BALB CChemotherapybusiness.industryCancerImmunotherapymedicine.diseaseKidney NeoplasmsKiller Cells NaturalSerous fluidmedicine.anatomical_structureDoxorubicinInterleukin-2FemaleImmunotherapyLymphbusinessJournal of Immunopharmacology
researchProduct

Seasons and Other Factors Affecting the Quality of Life of Asthmatic Children

2007

Amparo.Escribano@uv.es Objective: To study the effect of seasons on the health-related quality of life (HRQL) of asthmatic children. Methods: Four groups of asthmatic children 7 to 14 years old were recruited by pediatricians during each season of the year. Their HRQL was assessed by means of the Paediatric Asthma Quality of Life Questionnaire (PAQLQ). Other factors surveyed were asthma severity, atopy, medical treatment, immunotherapy, obesity, parental smoking, and anti-allergic measures. Results: The mean (SD) overall PAQLQ score was highest in summer at 6.2 (1.0) and lowest in autumn at 5.5 (1.2). The same trend was found for domains in summer and autumn, respectively: symptoms, 6.2 (1.…

MaleQuality of lifeOutpatient Clinics HospitalHealth StatusAsthma; Children; Immunotherapy; Quality of life; Seasons.Severity of Illness IndexAsthmaSeasons.Sex FactorsResidence CharacteristicsSpainPhysiciansUNESCO::CIENCIAS MÉDICAS ::Patología::HistopatologíaQuality of LifeHumansFemaleSeasonsImmunotherapyChildChildren:CIENCIAS MÉDICAS ::Patología::Histopatología [UNESCO]
researchProduct

Efficacy of immunoglobulins in gram-negative infections in experimentally induced peritonitis in the rat

1985

The effect of adjuvantly administered, newly developed immunoglobulin preparations in combination with an antibiotic is investigated by means of an animal experimental model. The animal model was peritonitis which was induced by a left-open colotomy in the rat. Administration of a combination therapy of immunoglobulins and an antibiotic succeeded in reducing lethality and shock index (according to Staub [15]) significantly by up to 50% as compared to the untreated control group. Using sub-therapeutic dosage of the antibiotic (50% of the human equivalent dose) the synergistic effect of the immunoglobulins could be confirmed clearly. A single summation of the offered immunoglobulin preparatio…

MaleTime FactorsGram-negative bacteriaCombination therapymedicine.drug_classmedicine.medical_treatmentAntibioticsPeritonitisPeritonitisPharmacologyImmunoglobulin EGram-Negative BacteriamedicineAnimalsLungChemotherapybiologybusiness.industryImmunization PassiveDrug SynergismBacterial InfectionsOrgan SizeGeneral MedicineImmunotherapybiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsRatsImmunologybiology.proteinAntibodybusinessResearch in Experimental Medicine
researchProduct